CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

 

Begin main content

Biosimilars — Regulatory, Health Technology Assessment, Reimbursement Trends, and Market Outlook

Last updated: January 19, 2018
Project Number: ES0317-000
Product Line: Environmental Scans
Result type: Report

The Environmental Scan identifies and compares information regarding the regulatory frameworks, HTA processes, and reimbursement trends of national and international organizations. It also provides a synopsis of the market outlook for biosimilars and their reference products in Canada.

The findings of this Environmental Scan are based on a literature search and correspondence with key informants from selected Health Technology Assessment organizations and with representatives from Federal, Provincial and Territorial drug plans and cancer agencies in Canada.